{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"Longest documented duration of time until progression to AML.","groups":[{"description":"Only nine of the eleven patients were evaluable for this outcome measure.","id":"OG000","title":"All Evaluable Patients"}],"paramType":"NUMBER","populationDescription":"Cycles are 28 days long. Analysis assessed the longest number of cycles completed on study until progression to AML.","reportingStatus":"POSTED","timeFrame":"approximately 4 years","title":"Time to Progression to Acute Myeloid Leukemia (AML)","type":"SECONDARY","unitOfMeasure":"cycles"}